This product is a recombinant Human antibody that recognizes PDCD1. The antibody was expressed in mammalian cells with chemically defined culture media and was purified by affinity chromatography.
Figure 1 Anti-PDCD1 Antibody (TAB-H55) in WB
Western blot analysis of TAB-H55 was performed with Recombinant Human PD1 Protein.
Goat Anti-Human IgG-HRP as a secondary antibody.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)
Figure 2 Anti-PDCD1 Antibody (TAB-H55) in ELISA
ELISA analysis of TAB-H55 was performed by coating with Recombinant Human PD1 Protein.
The Goat Anti-Human IgG-HRP as a secondary antibody.
Figure 3 Anti-PDCD1 Antibody (TAB-H55) in DB
Dot blot analysis of TAB-H55 was performed with PD-1 Protein, Human, Recombinant (His Tag).
TAB-H55 incubation concentration: 2ng/μL.
NC: Negative control PC: Positive control
Figure 4 SDS-PAGE analysis of anti-PD-1 antibody (Cat# TAB-H55)
The purified anti-PD-1 antibody (Cat# TAB-H55) was loaded in SDS-PAGE gels in β-mercaptoethanol-reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 5 SEC-HPLC analysis of anti-PD-1 antibody (Cat# TAB-H55)
Size exclusion chromatography (SEC-HPLC) is a technique of purity analysis and macromolecular separation based on molecule size. The purity of anti-PD-1 antibody (Cat# TAB-H55) was determined by this method with Agilent 1200 Series.
Figure 6 ELISA analysis of anti-PD-1 antibody (Cat# TAB-H55)
ELISA analysis of anti-PD-1 antibody (Cat# TAB-H55) was performed by coating with recombinant human PD-1 protein (His tag). Then blocked with BSA and incubated with anti-PD-1 antibodies. The HRP-conjugated goat anti-human IgG was used as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 7 Western blot analysis of anti-PD-1 antibody (Cat# TAB-H55)
Western blot analysis of anti-PD-1 antibody (Cat# TAB-H55) was performed by loading human PD-1 protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a NC membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with anti-PD-1 antibodies and HRP goat anti-human IgG was used as a secondary antibody (1/2000).
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 8 Dot blot analysis of anti-PD-1 antibody (Cat# TAB-H55)
Dot blot analysis of anti-PD-1 antibody (Cat# TAB-H55) was performed by coating with human PD-1 protein (His tag).
The anti-PD-1 antibody incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG was used as a secondary antibody (1/2000).
Figure 9 Sensorgram fit of human PD-1 analyte-binding anti-PD-1 antibody ligand (Cat# TAB-H55)
Dilute the antibody ligand (5 μg/mL) and antigen analyte with running buffer. The ligand was injected to sample channel (Fc2) at a flow rate of 10 μL/min to reach a capture level of about 400 RU. The analyte was injected to Fc1-Fc2 of the channel at a flow rate of 30 μL/min for an association phase of the corresponding time. The association and dissociation process were all handling in the running buffer. Repeat 6 cycles of analyte according to analyte concentrations in ascending order.
Figure 10 PD-L1 binding to PD-1 was blocked by anti-PD-1 antibody (Cat# TAB-H55), IC₅₀ = 442.9 ng/mL.
In a functional ELISA, the recombinant human PD‑1 protein (His tag) was coated at 2 µg/mL, 100 µL/well. Anti-PD-1 antibody (Cat# TAB-H55) were 3-fold serial diluted from 20 µg/mL, 100 µL/well. Coated PD-1 protein was incubated with the human PD-L1 mFc chimera (5 µg/mL) and anti-PD-1 antibody (Cat# TAB-H55). The PD-L1 binding to PD-1 was detected by HRP-goat anti-mouse IgG secondary antibody. Human IgG4 antibody (Cat# MOB-0408ZL, Creative Biolabs) was used as an isotype control.
Figure 11 Blockade of PD-1/PD-L1 interaction by anti-PD-1 antibody (Cat# TAB-H55) resulted in an increase of IFN-γ production.
PBMCs were stimulated with 2 μg/mL anti-CD3 antibody (Cat# TAB-0416CL, Creative Biolabs) and cultured for 144 hours with PD-1 antibody (Cat# TAB-H55, Creative Biolabs). Human IgG4 antibody (Cat# MOB-0408ZL, Creative Biolabs) was used as an isotype control. After cultivation, the supernatant was collected and the IFN-γ secretion level was analyzed using a human IFN gamma ELISA kit. The assay was performed in three parallel wells.
Wiese, Teresa. Pharmacological targeting of acid sphingomyelinase increases CD4\(^+\) Foxp3\(^+\) regulatory T cell subsets in patients with major depression. Diss. Universität Würzburg, 2022. https://doi.org/10.25972/OPUS-23347
The study investigates the pharmacological inhibition of acid sphingomyelinase (ASM) and its effects on human T cells, both in vitro and in vivo. The research aimed to analyze how inhibiting ASM affects the immune response, particularly focusing on the role of CD4+ Foxp3+ regulatory T cells (Tregs). By understanding the sphingolipid metabolism in these cells, the study explores how changes in sphingolipid content and functionality can influence immune cell behavior, which has implications for treating autoimmune and inflammatory diseases, as well as viral infections .
Creative Biolabs significantly contributed to this research by providing essential reagents. They supplied the PD-1 inhibiting monoclonal antibody pembrolizumab and the CTLA-4 inhibiting monoclonal antibody tremelimumab (CAT#: TAB-H55). These reagents were crucial for the experiments involving the modulation of immune responses, allowing the researchers to study the effects of blocking specific immune checkpoints. The use of these antibodies enabled detailed examination of the underlying mechanisms affected by ASM inhibition, thus advancing the understanding of T cell regulation and the potential therapeutic applications .
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-900 | Anti-Human PD-1/PDCD1/CD279 Recombinant Antibody (TAB-900) | IP, IF, FuncS, FC, Neut, ELISA, ICC | IgG1 - kappa |
TAB-0966CL-S(P) | Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0966CL-S(P)) | ELISA | Human scFv |
TAB-0975CL-S(P) | Human Anti-PDCD1 Recombinant Antibody; scFv Fragment (TAB-0975CL-S(P)) | ELISA | Human scFv |
TAB-0977CL-S(P) | Anti-Human PDCD1 Recombinant Antibody scFv Fragment (949gH1a) | FC | Humanized antibody |
TAB-0975CL-F(E) | Human Anti-PDCD1 Recombinant Antibody; Fab Fragment (TAB-0975CL-F(E)) | ELISA | Humanized Fab |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-H55, RRID: AB_3112038)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.